Details of the Drug Combination

General Information of Drug Combination (ID: DCKT16H)

Drug Combination Name

Bifemelane MK-4815

Indication

Disease Entry	Status	REF
Hepatoblastoma	Investigative	[1]

Component Drugs

Bifemelane DMU73F0

MK-4815 DMT9K74

Small molecular drug

N.A.

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HB3

Zero Interaction Potency (ZIP) Score: 9.823

Bliss Independence Score: 11.448

Loewe Additivity Score: 0.529

LHighest Single Agent (HSA) Score: 0.994

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Bifemelane

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Terminated	[2]

Bifemelane Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of MK-4815

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Investigative	[3]

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7.
3	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.